Frequently Asked Questions

Find answers to the questions researchers ask us most often—all in one place.

🛡 Are your products independently tested?

Yes. Every batch is verified by Janoshik using HPLC analysis.

Every product we supply undergoes independent HPLC testing by Janoshik Analytical, an unaffiliated peptide analysis laboratory based in the Czech Republic. Batch purity is consistently reported at greater than 99%.

When a Certificate of Analysis (COA) has been issued for the current batch, a printed copy is included with your order. If a printed certificate is not available, the latest verification can be viewed on our Purity page.

Each COA includes a unique verification code that can be checked directly through Janoshik’s online verification portal, allowing you to independently confirm the report’s authenticity. We also publish a guide explaining how to interpret Janoshik HPLC reports.

---

💧 Reconstituting BAC Water & Lyophilised Powder

Follow these four simple steps:

1. Clean the vial stopper with one of the supplied alcohol wipes and allow it to air dry.
2. Draw 2 mL of bacteriostatic water into an insulin syringe.
3. Slowly inject the water down the inside wall of the peptide vial rather than directly onto the powder.
4. Gently swirl until the powder has fully dissolved. Do not shake. Allow approximately 30 seconds before refrigerating.

The reconstitution guide printed inside the box lid can be used as a quick reference for future preparations.

---

💉 Using the Pen

Attach a New Needle

Clean the pen tip with an alcohol wipe before securely attaching a fresh sterile needle.

Prime the Pen

Turn the dose selector one click, point the pen upwards, and press the injection button until a small droplet appears. This confirms the pen has been primed and trapped air has been removed.

Set Your Research Dose

Rotate the dial to your required research dose. Depending on the calibration, each click typically delivers between 0.5 mg and 1 mg, with the display showing the total selected dose. As an example, a 6 mg dose generally corresponds to approximately 6–12 clicks.

Administration

Published research protocols describe subcutaneous administration into the abdomen, thigh, or upper arm. Hold the pen in place for approximately six seconds before removing it.

Dispose of the used needle in an approved sharps container, replace the pen cap, and return the pen to refrigerated storage.

Each pen provides the number of doses shown on the protocol guide for your selected size. Once empty, simply insert a replacement cartridge into the existing pen body. Current refill pricing is available using the calculator above.

Research use only. The information above reflects procedures described in published research literature and is not intended as medical or human-use guidance.

---

❄ Storage Guidelines

Lyophilised Powder

• Store sealed at 2–8°C
• Protect from direct light
• Stable for 24 months or longer
• Do not freeze

Reconstituted Solution

• Refrigerate at 2–8°C
• Recommended use within approximately 30 days
• Keep in the original glass vial
• Do not shake
• Discard if the solution becomes cloudy or changes colour

Bacteriostatic Water

• Refrigerate after opening
• Use within 30 days

---

📍 Administration Route Reported in Published Studies

Published pharmacokinetic and Phase II/III studies involving Tirzepatide commonly describe subcutaneous administration into the abdomen, thigh, or upper arm. Research protocols typically rotate administration sites to minimise local tissue irritation.

Research use only. This information is summarised from peer-reviewed scientific literature for reference purposes only. We do not provide dosing recommendations, administration instructions, or medical advice.

Reference: Jastreboff AM et al. (2022), NEJM SURMOUNT-1.

---

🎯 What Research Dose Should I Use?

Published Tirzepatide studies generally follow a gradual dose-escalation (titration) schedule. Researchers begin at the lowest protocol phase before increasing the dose at predefined weekly intervals. The maintenance phase highlighted in the protocol guide reflects where many published research cohorts remain during longer-term studies.

If you are beginning a new research protocol, start with Phase 1 for the full duration before progressing to the next stage. This gradual escalation mirrors the methodology used in published trials to minimise gastrointestinal events.

Researchers already familiar with Tirzepatide can select the relevant protocol phase to view estimated costs and product duration based on their chosen vial or pen size.

If your laboratory is following a customised protocol, contact us before ordering and we’ll help determine the most appropriate product size for your research schedule.

Research use only. All protocol information is derived from published peer-reviewed studies and is provided solely for scientific context. We do not provide medical advice or guidance relating to human use.

Reference: Jastreboff AM et al. (2022), NEJM SURMOUNT-1.

---

Key Information

Specification	Details
Compound	Tirzepatide
Research Category	Metabolic Research
Available Sizes	2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg
Pricing	From £71
Format	Lyophilised powder in sealed vial or pre-reconstituted pen
Verified Purity	>99% by HPLC (Janoshik Analytical)
Intended Use	In-vitro laboratory research only. Not for human consumption.

---

Chemical & Reference Data

The following specifications are compiled from publicly available scientific databases and peer-reviewed publications for laboratory reference.

Property	Value
Compound Class	Synthetic 39-amino-acid dual GIP/GLP-1 receptor agonist peptide
Molecular Formula	C225H348N48O68
Molecular Weight	4813.5 g/mol
CAS Number	2023788-19-2
PubChem CID	156588324
Amino Acid Residues	39
Mechanism	Dual agonist of GIP and GLP-1 receptors
Reported Half-Life	Approximately 120 hours in published primate studies
Solubility	Reconstitutes in bacteriostatic water for laboratory applications
Lyophilised Storage	Stable at 2–8°C for 24 months or longer
Reconstituted Storage	Store at 2–8°C and use within 28 days
Regulatory Status	MHRA approved in 2022 for type 2 diabetes; widely referenced in obesity research literature

---

Research Profile

• Dual GIP/GLP-1 receptor agonist
• Synthetic 39-amino-acid peptide
• Supplied as lyophilised powder for laboratory research
• Independently batch tested for purity
• Research use only

Tirzepatide is a synthetic peptide consisting of 39 amino acids and is described in the scientific literature as a dual agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It is supplied as a lyophilised powder exclusively for in-vitro laboratory research.

This description reflects published scientific literature and should not be interpreted as a claim regarding effects in humans.

---

Laboratory Handling

Tirzepatide is supplied as a freeze-dried powder in a sealed glass vial.

For laboratory reconstitution:

• Slowly add the required volume of bacteriostatic water down the inside wall of the vial.
• Avoid injecting directly onto the powder.
• Gently swirl until completely dissolved.
• Do not shake or vortex.
• Refrigerate the prepared solution at 2–8°C.
• Use within approximately 4–6 weeks.

Our Reconstitution Volume Calculator can be used to determine the resulting concentration (mg/mL).

State	Storage Temperature	Typical Shelf Life
Lyophilised	2–8°C or -20°C	Up to 24 months
Reconstituted	2–8°C	Approximately 4–6 weeks

---

Purity & Verification

Every Tirzepatide batch is independently analysed by Janoshik Analytical using HPLC testing. When available, a Certificate of Analysis accompanies each order and includes a unique verification code that can be authenticated directly with Janoshik. Reported purity consistently exceeds 99%.

---

Related Research Compounds

Researchers studying Tirzepatide frequently also work with:

• Semaglutide
• Liraglutide
• Mazdutide

Comparison guides are available for:

• Tirzepatide vs Retatrutide
• Tirzepatide vs Semaglutide

These comparisons examine mechanisms of action, laboratory handling, and pricing.

---

Key Literature References

• Coskun T. et al. (2018) – LY3298176, a novel dual GIP and GLP-1 receptor agonist (PMID: 31173901)
• Jastreboff AM et al. (2022) – Tirzepatide Once Weekly for the Treatment of Obesity (NEJM, PMID: 35658024)

These references are independent peer-reviewed publications. Vantix Bio is not affiliated with the authors or publishers.